↓ Skip to main content

Dove Medical Press

What’s in the pipeline? Drugs in development for autism spectrum disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
6 X users
googleplus
1 Google+ user

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
139 Mendeley
citeulike
1 CiteULike
Title
What’s in the pipeline? Drugs in development for autism spectrum disorder
Published in
Neuropsychiatric Disease and Treatment, February 2014
DOI 10.2147/ndt.s39516
Pubmed ID
Authors

Min Sung, Chee Hon Chin, Choon Guan Lim, Hwee Sen Alvin Liew, Chau Sian Lim, Espérance Kashala, Shih-Jen Weng

Abstract

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with both core symptoms and associated symptoms (eg, irritability, aggression, and comorbidities) that affect both the individual and the family/systems around them. There have been recent advances in the understanding of the underlying pathophysiology of ASD pertaining to genetics, epigenetics, neurological, hormonal, and environmental factors that contribute to the difficulties found in individuals with ASD. With this improved understanding, there has been a shift in the application of psychopharmacology in ASD and its related disorders. A literature review was conducted to examine research published in the last 5 years between different classes of psychotropic medications and ASD. The broad scope of the existing literature for the use of conventional medications is summarized and novel medications are discussed.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
France 1 <1%
Unknown 137 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 25 18%
Student > Ph. D. Student 24 17%
Student > Master 18 13%
Student > Bachelor 14 10%
Student > Doctoral Student 7 5%
Other 24 17%
Unknown 27 19%
Readers by discipline Count As %
Medicine and Dentistry 30 22%
Psychology 27 19%
Agricultural and Biological Sciences 20 14%
Neuroscience 7 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 15 11%
Unknown 36 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2014.
All research outputs
#7,148,499
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#906
of 3,132 outputs
Outputs of similar age
#78,766
of 322,718 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#14
of 58 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.